FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046303902> ?p ?o ?g. }

• W3046303902 endingPage "654" @default.
• W3046303902 startingPage "646" @default.
• W3046303902 abstract "Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. Objectives To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. Methods We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. Results In total, 205 patients were included of whom 39 (19%) were treatment-naïve. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade ≥3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. Conclusions In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials." @default.
• W3046303902 created "2020-08-07" @default.
• W3046303902 creator A5013999649 @default.
• W3046303902 creator A5016242784 @default.
• W3046303902 creator A5023096734 @default.
• W3046303902 creator A5028802786 @default.
• W3046303902 creator A5031331400 @default.
• W3046303902 creator A5041744564 @default.
• W3046303902 creator A5057884204 @default.
• W3046303902 creator A5073812314 @default.
• W3046303902 creator A5075799828 @default.
• W3046303902 creator A5085154907 @default.
• W3046303902 creator A5087876040 @default.
• W3046303902 creator A5090339651 @default.
• W3046303902 date "2020-08-26" @default.
• W3046303902 modified "2023-10-02" @default.
• W3046303902 title "Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib" @default.
• W3046303902 cites W1891620832 @default.
• W3046303902 cites W1966083884 @default.
• W3046303902 cites W2071549499 @default.
• W3046303902 cites W2108206643 @default.
• W3046303902 cites W2113895281 @default.
• W3046303902 cites W2163709153 @default.
• W3046303902 cites W2233614027 @default.
• W3046303902 cites W2260369425 @default.
• W3046303902 cites W2318933236 @default.
• W3046303902 cites W2399623634 @default.
• W3046303902 cites W2544982242 @default.
• W3046303902 cites W2557801192 @default.
• W3046303902 cites W2560322684 @default.
• W3046303902 cites W2623762297 @default.
• W3046303902 cites W2787916641 @default.
• W3046303902 cites W2790385276 @default.
• W3046303902 cites W2804951327 @default.
• W3046303902 cites W2892491666 @default.
• W3046303902 cites W2902034029 @default.
• W3046303902 cites W2941780980 @default.
• W3046303902 cites W2973195462 @default.
• W3046303902 cites W2978550355 @default.
• W3046303902 cites W2980937306 @default.
• W3046303902 doi "https://doi.org/10.1111/ejh.13499" @default.
• W3046303902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32736410" @default.
• W3046303902 hasPublicationYear "2020" @default.
• W3046303902 type Work @default.
• W3046303902 sameAs 3046303902 @default.
• W3046303902 citedByCount "28" @default.
• W3046303902 countsByYear W30463039022021 @default.
• W3046303902 countsByYear W30463039022022 @default.
• W3046303902 countsByYear W30463039022023 @default.
• W3046303902 crossrefType "journal-article" @default.
• W3046303902 hasAuthorship W3046303902A5013999649 @default.
• W3046303902 hasAuthorship W3046303902A5016242784 @default.
• W3046303902 hasAuthorship W3046303902A5023096734 @default.
• W3046303902 hasAuthorship W3046303902A5028802786 @default.
• W3046303902 hasAuthorship W3046303902A5031331400 @default.
• W3046303902 hasAuthorship W3046303902A5041744564 @default.
• W3046303902 hasAuthorship W3046303902A5057884204 @default.
• W3046303902 hasAuthorship W3046303902A5073812314 @default.
• W3046303902 hasAuthorship W3046303902A5075799828 @default.
• W3046303902 hasAuthorship W3046303902A5085154907 @default.
• W3046303902 hasAuthorship W3046303902A5087876040 @default.
• W3046303902 hasAuthorship W3046303902A5090339651 @default.
• W3046303902 hasBestOaLocation W30463039022 @default.
• W3046303902 hasConcept C119060515 @default.
• W3046303902 hasConcept C126322002 @default.
• W3046303902 hasConcept C141071460 @default.
• W3046303902 hasConcept C143998085 @default.
• W3046303902 hasConcept C167135981 @default.
• W3046303902 hasConcept C197934379 @default.
• W3046303902 hasConcept C2777938653 @default.
• W3046303902 hasConcept C2778461978 @default.
• W3046303902 hasConcept C2778715236 @default.
• W3046303902 hasConcept C2779878957 @default.
• W3046303902 hasConcept C2908647359 @default.
• W3046303902 hasConcept C44249647 @default.
• W3046303902 hasConcept C535046627 @default.
• W3046303902 hasConcept C71924100 @default.
• W3046303902 hasConcept C72563966 @default.
• W3046303902 hasConcept C99454951 @default.
• W3046303902 hasConceptScore W3046303902C119060515 @default.
• W3046303902 hasConceptScore W3046303902C126322002 @default.
• W3046303902 hasConceptScore W3046303902C141071460 @default.
• W3046303902 hasConceptScore W3046303902C143998085 @default.
• W3046303902 hasConceptScore W3046303902C167135981 @default.
• W3046303902 hasConceptScore W3046303902C197934379 @default.
• W3046303902 hasConceptScore W3046303902C2777938653 @default.
• W3046303902 hasConceptScore W3046303902C2778461978 @default.
• W3046303902 hasConceptScore W3046303902C2778715236 @default.
• W3046303902 hasConceptScore W3046303902C2779878957 @default.
• W3046303902 hasConceptScore W3046303902C2908647359 @default.
• W3046303902 hasConceptScore W3046303902C44249647 @default.
• W3046303902 hasConceptScore W3046303902C535046627 @default.
• W3046303902 hasConceptScore W3046303902C71924100 @default.
• W3046303902 hasConceptScore W3046303902C72563966 @default.
• W3046303902 hasConceptScore W3046303902C99454951 @default.
• W3046303902 hasFunder F4320307770 @default.
• W3046303902 hasFunder F4320320943 @default.
• W3046303902 hasFunder F4320325957 @default.

• next